Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Idiopathic (Essential) Hypertension-Pipeline Review, H1 2015

Idiopathic (Essential) Hypertension-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Idiopathic (Essential) Hypertension-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Idiopathic (Essential) Hypertension-Pipeline Review, H1 2015', provides an overview of the Idiopathic (Essential) Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Idiopathic (Essential) Hypertension and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Idiopathic (Essential) Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Idiopathic (Essential) Hypertension pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Idiopathic (Essential) Hypertension Overview 7

Therapeutics Development 8

Pipeline Products for Idiopathic (Essential) Hypertension-Overview 8

Pipeline Products for Idiopathic (Essential) Hypertension-Comparative Analysis 9

Idiopathic (Essential) Hypertension-Therapeutics under Development by Companies 10

Idiopathic (Essential) Hypertension-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Idiopathic (Essential) Hypertension-Products under Development by Companies 14

Idiopathic (Essential) Hypertension-Companies Involved in Therapeutics Development 15

Bayer AG 15

Chong Kun Dang Pharmaceutical Corp. 16

Daiichi Sankyo Company, Limited 17

Eli Lilly and Company 18

Jiangsu Hengrui Medicine Co., Ltd. 19

Lee's Pharmaceutical Holdings Limited 20

PhaseBio Pharmaceuticals, Inc. 21

Quantum Genomics SA 22

Takeda Pharmaceutical Company Limited 23

Idiopathic (Essential) Hypertension-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Combination Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 31

Drug Profiles 33

(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide)-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

(amlodipine besylate + candesartan)-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

(nifedipine + candesartan cilexetil)-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

azilsartan medoxomil-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

carvedilol phosphate ER-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

carvedilol SR-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

CS-3150-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

LY-2623091-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

PB-1120-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

QGC-001-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

rostafuroxin-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Idiopathic (Essential) Hypertension-Recent Pipeline Updates 48

Idiopathic (Essential) Hypertension-Dormant Projects 51

Idiopathic (Essential) Hypertension-Product Development Milestones 53

Featured News & Press Releases 53

Jun 12, 2013: Lee's Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2015 8

Number of Products under Development for Idiopathic (Essential) Hypertension-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Idiopathic (Essential) Hypertension-Pipeline by Bayer AG, H1 2015 15

Idiopathic (Essential) Hypertension-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 16

Idiopathic (Essential) Hypertension-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 17

Idiopathic (Essential) Hypertension-Pipeline by Eli Lilly and Company, H1 2015 18

Idiopathic (Essential) Hypertension-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 19

Idiopathic (Essential) Hypertension-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 20

Idiopathic (Essential) Hypertension-Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 21

Idiopathic (Essential) Hypertension-Pipeline by Quantum Genomics SA, H1 2015 22

Idiopathic (Essential) Hypertension-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Assessment by Combination Products, H1 2015 25

Number of Products by Stage and Target, H1 2015 27

Number of Products by Stage and Mechanism of Action, H1 2015 29

Number of Products by Stage and Route of Administration, H1 2015 30

Number of Products by Stage and Molecule Type, H1 2015 32

Idiopathic (Essential) Hypertension Therapeutics-Recent Pipeline Updates, H1 2015 48

Idiopathic (Essential) Hypertension-Dormant Projects, H1 2015 51

Idiopathic (Essential) Hypertension-Dormant Projects (Contd..1), H1 2015 52

List of Figures

Number of Products under Development for Idiopathic (Essential) Hypertension, H1 2015 8

Number of Products under Development for Idiopathic (Essential) Hypertension-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Assessment by Monotherapy Products, H1 2015 24

Assessment by Combination Products, H1 2015 25

Number of Products by Top 10 Targets, H1 2015 26

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Top 10 Molecule Types, H1 2015 31

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bayer AG

Chong Kun Dang Pharmaceutical Corp.

Daiichi Sankyo Company, Limited

Eli Lilly and Company

Jiangsu Hengrui Medicine Co., Ltd.

Lee's Pharmaceutical Holdings Limited

PhaseBio Pharmaceuticals, Inc.

Quantum Genomics SA

Takeda Pharmaceutical Company Limited

Idiopathic (Essential) Hypertension Therapeutic Products under Development, Key Players in Idiopathic (Essential) Hypertension Therapeutics, Idiopathic (Essential) Hypertension Pipeline Overview, Idiopathic (Essential) Hypertension Pipeline, Idiopathic (Essential) Hypertension Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com